BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
NEW YORK, March 28, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Stemline Therapeutics, Inc. (“Stemline”) (NASDAQ:STML) (1) pursuant and/or traceable to Stemline's secondary public offering on or about January 20, 2017; and/or (2) on the open market between January 6, 2017 and February 1, 2017, inclusive. You are hereby notified that Levi & Korsinsky has commenced the class action Braswell v. Stemline Therapeutics, et al. (Case No. 1:17-cv-00853) in the USDC for the Southern District of New York. Click here to view the complaint. To get more information go to:
http://www.zlk.com/pslra/stemline-therapeutics
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that during the class period the Company made materially false and/or misleading statements and/or failed to disclose that: (i) a patient had died in the BPDCN Trial from capillary leak syndrome immediately prior to the Company’s stock offering despite consistently stating that capillary leak syndrome was a potential side-effect of SL-401; and (ii) SL-401’s safety profile did not remain predictable and manageable over increasing treatment duration, drug exposure, and patient experience as represented by the Defendants.
Take Action: if you suffered a loss in Stemline Therapeutics you have until April 4, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
